FDA warns on use of certain surgical mesh in breast reconstruction

Two brands of surgical mesh used off-label in breast reconstruction surgery have had “significantly higher major complication rates,” according to an FDA analysis.

Patients implanted with  FlexHD by MTF Biologics and AlloMax by BD had higher rates of explantation, reoperations and infections two years after surgery when compared with patients who received one of two other brands of surgical mesh or no mesh, the agency said late yesterday.

Get the full story on our sister site, Medical Design & Outsourcing.